Trial Profile

A MULTICENTER RANDOM ASSIGNMENT PHASE II STUDY OF IRINOTECAN AND ALVOCIDIB (FLAVOPIRIDOL) VERSUS IRINOTECAN ALONE FOR PATIENTS WITH P53 WILD TYPE GASTRIC ADENOCARCINOMA (NCI 8060).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alvocidib (Primary) ; Irinotecan (Primary)
Indications Gastric cancer
Focus Registrational; Therapeutic Use

Most Recent Events

09 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
06 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
05 Jun 2012 Interim results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com